Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells in situ represents a promising strategy for cardiac regeneration. A combination of 3 cardiac transcription factors, Gata4, Mef2c, and Tbx5 (GMT), can convert fibroblasts into induced cardiomyocyte-like cells, albeit with low efficiency in vitro.
H eart failure affects 23 million people worldwide and is typically caused by loss of cardiomyocytes or dysfunction of existing cardiomyocytes. 1 A common cause of cardiomyocyte loss is ischemic heart disease leading to myocardial infarction, and because of the limited ability of the heart to regenerate, damage is permanent and progressive. Despite advances in medical therapy, there is currently no strategy to restore muscle mass other than orthotopic heart transplantation, which is limited in number and long-term efficacy. Cell-based therapies used in human trials to date have demonstrated that transplanted cells do not become cardiomyocytes in significant numbers and fail to persist in the heart. 2 Transplantation of pluripotent stem cellderived cardiomyocytes is being tested and could be of value if issues of survival, maturity, and electrophysiological integration can be overcome. 3 In situ reprogramming of cells with lineage-enriched transcription factors (TFs) into the cell type lost in disease represents a promising alternative to cell-based approaches to tissue regeneration. 4 In the heart, an abundant pool of nonmyocytes, largely cardiac fibroblasts, can be harnessed for conversion into induced cardiomyocyte-like cells (iCMs) with a combination of TFs. 4 In rodents, direct intramyocardial viral introduction of 3 core cardiac TFs, Gata4, Mef2c, and Tbx5 (GMT), after coronary ligation results in conversion of nonmyocytes into iCMs that electrically couple with existing cardiomyocytes, improve cardiac function, and decrease scar size. 5 However, the efficiency remains limited, particularly in vitro, where the majority of cardiomyocytes are only partially reprogrammed. 4 The signals present in vivo resulting in improved quality of reprogramming remain unknown but suggest that alteration of culture conditions or signaling pathways could enhance in vitro, and possibly in vivo, cardiac reprogramming.
Since the first successful generation of iCMs, 4 we and others have taken a candidate approach to identify combinations of genes or conditions that enhance cardiac reprogramming. By alteration of the stoichiometry of GMT, 6 including additional factors, or manipulation of signaling pathways, the quality and efficiency of iCMs generated in vitro can be improved. [7] [8] [9] [10] [11] [12] [13] [14] In most cases, improvements in efficiency were found largely in mouse embryonic fibroblasts (MEFs) in the presence of GMT plus additional TFs, with limited improvement in primary cardiac fibroblasts. Although recent siRNA-mediated knockdown of Bmi1 improved efficiency of cardiac fibroblast reprogramming in vitro, 15 it remains to be determined whether any of the above approaches enhance in vivo reprogramming in mice or influence reprogramming of human cardiac fibroblasts, both of which are critical to future translation.
Here, we report the first high-throughput chemical screening in primary mouse cardiac fibroblasts and reveal pathways that can be modulated to enhance cardiomyocyte reprogramming from cardiac fibroblasts using the minimal combination of GMT. Chemical screening converged on transforming growth factor-β (TGF-β) and WNT signaling pathways as barriers to reprogramming. We show that chemically inhibiting both pathways together boosts the efficiency, quality, and speed of converting postnatal mouse or human cardiac fibroblasts to cardiomyocyte-like cells in vitro. Most important, in vivo delivery of these inhibitors along with GMT in an acute model of mouse myocardial infarction improved cardiac function, generation of iCMs, and scarring compared with GMT alone. These findings provide the first demonstration of a combined gene therapy and drug approach to cardiac regeneration in vivo and pave the way for new translational approaches for heart failure.
METHODS Tissue Collection and Fibroblast Isolation
The animal procedures followed were in accordance with the institutional guidelines and approved by the University of California, San Francisco Institutional Animal Care and Use Committee. Mouse cardiac fibroblasts were isolated from P0-P4 α-myosin heavy chain-green fluorescent protein (α-MHC-GFP) transgenic neonates with the migration method as previously described. 4, 16 Heart tissue was isolated, minced, and cultured on gelatin-coated plates in fibroblast explant media (20% FBS in Iscove modified Dulbecco medium) for 1
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What Is New?
• Using a high-throughput chemical screen in postnatal mouse cardiac fibroblasts, we found that transforming growth factor-β and WNT inhibition enhances transcription factor-based direct reprogramming of cardiac fibroblasts to induced cardiomyocyte-like cells in vitro and in vivo.
• A combination of transforming growth factor-β and WNT chemical inhibitors increases quality, quantity, and speed of direct reprogramming, resulting in improved cardiac function after injury.
• These chemical inhibitors enhanced human cardiac reprogramming and reduced the number of transcription factors needed for human cardiac reprogramming.
What Are the Clinical Implications?
• The enhancement in quality and quantity of cardiac reprogramming with the help of small molecules in vivo and in human cells moves this technology closer to translation. • These findings, if validated in large animals, could facilitate a combined gene therapy and small-molecule approach to heart failure. A, Schematic for the small-molecule screening strategy using primary mouse cardiac fibroblasts (Thy1 + cells) from (Continued ) week at 37°C. Migrated cells were washed twice with PBS, digested in 0.05% trypsin for 5 minutes, and quenched with fibroblast explant media. Tissues were filtered through a 70-μm filter and pelleted. Pelleted cells were stained for 20 minutes with Thy-1-APC (Ebioscience, anti-mouse/rat CD90.1 thy-1.1, No. 17-0900-82) and washed twice with PBS as previously described. APC + cells were isolated by fluorescenceactivated cell sorting (FACS), plated onto 10-cm gelatin-coated plates, and used fresh (without freezing) for all studies. All cell preparations were tested for mycoplasma contamination.
Reprogramming of Mouse Cardiac Fibroblasts to iCMs
Direct conversion of Thy1 + cardiac fibroblasts to iCMs was completed as previously described. 16 pMXs-Gata4, pMXsMef2c, pMXs-Tbx5, polycystronic pMXs-Mef2c-Gata4-Tbx5 (GMT polycystronic), or pMXs-dsRed was constructed as previously described. 4, 17 Retroviral vectors were packaged with Fugene HD (Roche) and delivered in OptiMEM (10 μg) to 15-cm plates containing ≈80% confluent PlatE cells in fibroblast explant media, as previously described. 5 Viral supernatant was collected 48 hours after transfection and used to infect cardiac fibroblasts with the addition of 0.6 μg/mL polybrene (Chemicon) and added to cardiac fibroblasts at day −1. After 24 hours, the culture medium was replaced with cardiomyocyte culture medium (iCM medium) 16 at day 0 and replaced every 3 to 4 days. We used the 3 separate Gata4, Mef2c, and Tbx5 retroviruses in the initial drug screening and the in vivo experiments; however, for further in vitro experiments after the initial screening, we used a GMT polycystronic retrovirus.
Methods in the online-only Data Supplement provides more details on drug screening, FACS analyses and sorting, Western blotting, real-time polymerase chain reaction, RNA-sequencing (RNA-seq) analyses, animal experiments, magnetic resonance imaging, isolation of adult cardiomyocytes, calcium-transient assessment, action potential recordings, and human cardiac reprogramming.
Statistical Analyses
Differences between groups were examined for statistical significance with unpaired Student t tests or ANOVA. A value of P<0.05 was regarded as significant. Error bars indicate SEM.
RESULTS

SB431542 and XAV939 Combinatorially Enhance Efficiency of Cardiac Reprogramming
To identify biological pathways that could be manipulated to improve cardiac reprogramming, we used a chemical biology approach involving an unbiased small molecule library screen. We purified Thy1 + mouse cardiac fibroblasts from transgenic mice containing GFP under control of the cardiomyocyte-specific α-MHC promoter. 4 Cardiac reprogramming was induced with GMT retroviruses. Potential iCMs were detected by activation of the α-MHC-driven GFP reporter. After optimizing this method of direct reprogramming in a 384-well format, we screened a total of 5500 compounds from libraries of toxicologically tested compounds (eg, Ding laboratory, 18 LOPAC, 19 TOCRIS, 20 and SPECTRUM 21 small-molecule libraries) using highthroughput, high-content imaging ( Figure 1A ). Compounds were added 1 day after GMT transduction, and α-MHC-GFP + cells were quantified after 2 weeks. We identified 26 top hits with a z score >5 ( Figure 1B) , and after validation, these hits increased the percentage of GFP + iCMs by 2-to 6-fold ( Figure 1C ). The top hits included 3 molecules that inhibit TGF-β signaling (SB431542, 22 LDN-193189, 23 and dexamethasone [24] [25] [26] ), 3 molecules that inhibit WNT signaling (XAV939, 27 IWR1, 28 and myricetin 29 ), and 1 molecule that inhibits both WNT and TGF-β signaling (D4476) 30, 31 ( Figure 1C) . Several of the top hits also inhibited inflammatory pathways (DHA, piroxicam), as does dexamethasone, although they did not enhance reprogramming as robustly as the WNT or TGF-β inhibitors. The multiple chemical modulators of the same pathways suggested that these signaling pathways reliably affect cardiac reprogramming, and we focused further analysis in this area.
To identify which of the putative WNT or TGF-β inhibitor compounds most effectively improve GMT-reprogramming quality and to exclude false positives, we conducted quantitative real-time polymerase chain reaction for a panel of endogenous cardiac and fibroblast genes 2 weeks after initiating conversion with each compound. SB431542 was the most efficient of the TGF-β inhibitors at downregulating fibroblast gene expression and XAV939 was the most efficient of the WNT inhibitors at activating cardiac gene expression at 2 weeks of reprogramming ( Figure 1D ). We also found that SB431542 (2.6 µmol/L; Figure IA in the online-only Data Supplement) was most effective if added 24 hours after GMT infection (day 1 of reprogramming; Figure 1E ). We tested various doses and timing of XAV939 to identify its optimal timing and concentration. We found that 5 µmol/L was the most effective dose and resulted in similar enhancement when added at any time during the first 8 days of reprogramming ( Figure IB 2 small molecules, we found that maximum reprogramming efficiency was achieved by adding XAV939 at day 2 (48 hours) of reprogramming, after adding SB431542 at day 1. This protocol resulted in a >8-fold increase in cardiac reprogramming, as indicated by the increase in α-MHC-GFP + iCMs ( Figure 1F ). Furthermore, removal of compounds at serial days of reprogramming revealed that the compounds were dispensable after ≈1 week of reprogramming ( Figure 1G ). Addition of dexamethasone did not further enhance reprogramming (data not shown).
SB431542 and XAV939 Enhance the Efficiency, Speed, and Quality of iCM Generation
After validating and optimizing the timing, dose, and conditions for adding small molecules to the reprogramming cocktail, we treated GMT-overexpressing fibroblasts with SB431542 (2.6 µmol/L) at day 1 and XAV939 (5 µmol/L) at day 2. This combination of SB431542 at day 1 and XAV939 at day 2 significantly increased GMT-induced reprogramming efficiency within 2 weeks to ≈30% α- MHC-GFP + iCMs from primary cardiac fibroblasts compared with ≈15% in the presence of either compound and 4% without any compounds (Figure 2A and 2B). After 4 weeks of reprogramming, each compound alone resulted in a doubling of the number of iCMs positive for α-MHC and cardiac troponin-T (TNT), whereas reprogramming in the presence of both compounds resulted in a 4-fold increase in the number of double-positive iCMs compared with GMT alone ( Figure 2C ). With SB431542 or XAV939, beating cells appeared as early as 3 weeks after GMT infection. It is remarkable that with the combination of SB431542 and XAV939, beating cells appeared as early as 1 week, compared with 6 to 8 weeks with GMT alone ( Figure 3A and Movies I and II in the online-only Data Supplement). We also observed clear cardiac TNT staining and advanced sarcomere organization in iCMs after only 2 weeks of reprogramming with GMT+SB431542/XAV939 versus 4 weeks with GMT plus either compound alone 16 ( Figure 3B ). Moreover, >≈50% of the cells possessed spontaneous calcium transients within 4 weeks of reprogramming in the presence of the 2 compounds ( Figure 3C and Movie III in the online-only Data Supplement).
We analyzed gene expression profiles in iCMs 1, 2, 3, 5, and 6 weeks after cardiac reprogramming using RNA-seq. The data analysis was performed on the average values of fragments per kilobase of exon per million fragments mapped of 2 replicates in each group. At 1, 2, and 3 weeks, iCMs treated with SB431542 and XAV939 (GMTc) had a more cardiomyocyte-like transcriptional profile compared with GMT iCMs as reflected by principal component analysis and analysis of the cardiomyocyte and fibroblast genes that were inadequately regulated with GMT alone ( Figure IID in the onlineonly Data Supplement). iCMs treated for 3 weeks with GMT+SB431542 and XAV939, but not iCMs treated with a single compound, had a more cardiomyocyte-like transcriptional profile as reflected by principal component analysis ( Figure 4A ). Reprogramming with GMTc for 5 or 6 weeks resulted in gene expression profiles closer to adult mouse ventricular cardiomyocytes than reprogramming with GMT alone ( Figure 4A ). Furthermore, iCMs reprogrammed with GMTc for 3, 5, or 6 weeks significantly downregulated genes with Gene Ontology (GO) terms related to TGF-β and WNT signaling, similar to cardiomyocytes ( Figure 4B ). Comparing gene expression profiles between GMT and GMTc at 5 weeks, we found that the top differentially regulated GO terms were related to regulation of extracellular matrix, ion channels, and muscle formation ( Figure 4C ). On closer analysis of the most highly expressed cardiac-contractile, ion-handling, and extracellular matrix genes ( Figure 4D ), we found that the compounds brought the expression of these genes very close to that of adult cardiomyocytes, albeit not completely. Thus, SB431542 and XAV939 together increased not only the quantity but also the quality and speed of cell-fate conversion in vitro.
SB431542 and XAV939 Function by Reducing TGF-β-and WNT-Dependent Barriers to Cardiac Reprogramming
Next, we investigated the mechanisms by which SB431542 and XAV939 function, specifically testing whether they affect reprogramming through TGF-β and WNT signaling, respectively. Phosphorylation of SMAD2/3 (indicator of TGF-β activation) and the active form of β catenin (indicator of WNT activation) was significantly reduced ( Figure IIA and IIB in the online-only Data Supplement) in the GMTc setting compared with GMT alone. We also observed that activating TGF-β or canonical WNT signaling reversed the reprogramming efficiency gains induced by SB431542 or XAV939, respectively. Adding excess TGF-β1 ligand during reprogramming reversed the effect of SB431542 and partially inhibited the combined effect of SB431542 and XAV939; however, BMP4, which regulates other aspects of TGF-β signaling, did not significantly affect cardiac reprogramming ( Figure 4E ). Moreover, overexpression of constitutively active SMAD2 or SMAD3 (TGF-β signaling effectors) abolished cardiac reprogramming enhancement by SB431542 ( Figure 4G ). Because SB431542 inhibits activin receptor-like kinase (ALK) 4 and ALK5 receptors, 22 we tested the effect of knocking down ALK4 or ALK5 with siRNA on direct cardiac reprogramming. An ≈80% reduction of ALK4 or ALK5 ( Figure IIC in the onlineonly Data Supplement) enhanced direct cardiac reprogramming, similar to SB431542 ( Figure 4H ). Similarly, WNT3a, which activates canonical WNT signaling, partially blocked the effects of SB431542 and XAV939 on cardiac reprogramming; however, activating the noncanonical WNT pathway through WNT5 or WNT11 showed a moderate, but not statistically significant, reduction in reprogramming. Furthermore, adding the glycogen syn- thase kinase 3β inhibitor CHIR99021, which activates the WNT pathway, completely reversed the combined effect of SB431542 and XAV939 ( Figure 4F ). Thus, SB431542 and XAV939 appear to enhance cardiac reprogramming by inhibiting TGF-β and WNT signaling, respectively.
Our primary GO enrichment analysis of the RNA-seq data from 3-week reprogrammed iCMs in the presence of SB431542, XAV939, or SB431542+XAV939 highlighted the major downstream modification by the compounds associated with an increase in the efficiency of reprogramming ( Figure 5 ). SB431542-reprogrammed iCMs showed downregulation in genes that are enriched in GO terms related to fibrotic signal and extracellular matrix formation, consistent with what has been reported in other reprogramming settings. 13, 14 However, XAV939-reprogrammed iCMs possessed downregulation in genes involved primarily in chromatin modulation, DNA packaging, and nucleosome organization, which indicates that inhibition of WNT signaling may act on chromatin modulation to facilitate GMT chromatin binding at the cardiac gene sites, as previously reported for WNT signaling in other cell types. 32 However, iCMs reprogrammed in the presence of both SB431542 and XAV939 showed specific upregulation of GO terms related to calcium handling, ion channels, fatty acid metabolism, and mitogenactivated protein kinase signaling, all consistent with a more differentiated cardiomyocyte state ( Figure 5 ).
TGF-β and WNT Inhibition Enhances Cardiac Reprogramming In Vivo
We previously showed that intramyocardial injection of GMT successfully reprogrammed fibroblasts into iCMs in vivo, increased heart function, and decreased scar size after injury, but improvement in the technology is likely necessary for further in vivo translation. 5 We tested the effects of inhibiting TGF-β and WNT signaling on cardiac reprogramming in vivo by injecting SB431542 (10 mg·kg ) 34 intraperitoneally every day for 2 weeks after coronary ligation and intramyocardial injection of GMT-encoding retrovirus (GMTc). All the surgeries, echocardiography, and analyses were conducted blindly, and animals were decoded after all data were collected. GMTc significantly enhanced cardiac function compared to treatment with GMT alone, as reflected by changes in the ejection fraction assessed by echocardiography ( Figure 6A ). The improved function occurred as early as 1 week after myocardial infarction, consistent with our in vitro observations showing an acceleration of reprogramming with beating cells at 1 week, and the functional improvement persisted over 12 weeks. The inhibitors alone did not significantly affect cardiac function. At 12 weeks after myocardial infarction, we conducted blinded magnetic resonance imaging to evaluate heart structure and function because it is the most accurate form of measurement. Thick muscle within the infarct region was observed only in the group treated with GMTc, even at the apex of the heart (Figure 6B) . Heart function revealed by magnetic resonance imaging was significantly improved in all animals treated with GMTc compared with GMT alone, as assessed by changes in stroke volume, ejection fraction, and cardiac output ( Figure 6C ).
We conducted histological analyses to quantify the scar size and to detect the presence of muscle within the infarct area of treated hearts. Consistent with our in vivo imaging observations, we found that scar size was significantly decreased further with GMTc compared with GMT alone ( Figure 6C ). We also observed threads of myocytes that developed within the infarct site of hearts treated with GMT alone, similar to our previous report 5 ; however, in hearts isolated from animals treated with GMTc, we observed thick bands of myocytes throughout the infarct zone ( Figure 6D and Figure IIIA in the onlineonly Data Supplement). To investigate whether this remuscularization was due to reprogramming of resident fibroblasts, we crossed ROSA-Lox-Stop-Lox-YFP mice with periostin-Cre mice to generate ROSA-YFP/periostinCre lineage-tracing mice. These mice express yellow fluorescent protein (YFP) only in nonmyocytes-largely fibroblasts-and in their descendants and thereby distinguish reprogrammed cardiomyocytes from endogenous cardiomyocytes ( Figure IIIB in the online-only Data Supplement). We previously validated this system, evaluating for potential of false-positive data from cell-cell fusion events or leakiness of the Cre. 5 We found that the re- muscularization around the infarct area was due to newly formed iCMs because these cells stained positive for TNT and the periostin-YFP reporter ( Figure 6D and Figure  IIID in the online-only Data Supplement). However, we did not find any YFP + cells also positive for TNT in the control groups or in areas distal to the infarct site ( Figure 6D and Figure IIIC in the online-only Data Supplement).
To assess the functionality and quality of the in vivo iCMs, we used a Langendorff preparation to isolate iCMs from ROSA-YFP/periostin-Cre mice and analyzed histologic sections. The number of YFP + iCMs significantly increased by 5-fold in animals treated with GMTc compared with GMT alone ( Figure 6E ). Almost all iCMs isolated from either GMT-or GMTc-treated mice were rod shaped and formed well-organized sarcomere structures, similar to adult cardiomyocytes ( Figure 7A ). All cells isolated from GMT-treated mice exhibited spontaneous calcium transients, whereas endogenous cardiomyocytes were quiescent until electrically stimulated, reflecting their greater hyperpolarization. In contrast, >70% of the cells isolated from GMTc mice were quiescent but became contractile on electric stimulation, indicating a greater similarity to endogenous cardiomyocytes ( Figure 7B and Movies IV-XI in the online-only Data Supplement). In addition, analysis of the calcium transients revealed that the calcium amplitude and the time constant of calcium decay (τ) of GMTc iCMs were more similar to control cardiomyocytes than GMT iCMs ( Figure IVA in the onlineonly Data Supplement). Although electrophysiological analysis of the action potential of GMT iCMs and GMTc iCMs by patch clamp showed similar maximum diastolic potential at ≈−80 mV, the action potential amplitude and its duration were significantly greater in GMTc iCMs compared with GMT iCMs and similar to endogenous cardiomyocytes ( Figure IVB in the online-only Data Supplement). These data indicate that GMTc iCMs are closer to adult control cardiomyocytes in terms of functionality compared with GMT iCMs. We also conducted RNA-seq to compare whole-transcriptome changes between endogenous cardiomyocytes, GMT iCMs, and GMTc iCMs isolated from in vivo reprogrammed hearts. The gene expression signatures of GMT or GMTc iCMs were more similar to adult ventricular cardiomyocytes than neonatal cardiomyocytes, with GMTc iCMs being closer to adult cardiomyocytes as reflected by principal component analysis ( Figure 7C ). In addition, compared with neonatal cardiomyocytes, GMT iCMs and GMTc iCMs displayed more fully downregulated genes with GO terms related to TGF-β and WNT signaling, similar to adult cardiomyocytes ( Figure 7D ). However, GO analysis for the genes that were differentially regulated by at least 2-fold between GMT and GMTc iCMs revealed downregulation of genes involved in cell division and mitosis in GMTc and upregulation of metabolic genes and cAMP-related genes, consistent with a more differentiated state ( Figure 7E ). Focusing on changes in highly expressed major cardiac and fibroblast genes, we found that GMTc iCMs displayed a more complete upregulation of cardiac genes compared with GMT iCMs (Figure 7F ).
TGF-β and WNT Inhibitors Enhance Reprogramming of Human Adult Cardiac Fibroblasts
We previously reported that GMT was insufficient to reprogram human fibroblasts, but the addition of ESRRG and MESP1 resulted in generation of iCMs, and inclusion of myocardin and ZFPM2 (7F) could reprogram human cells to a quality similar to that in mouse cells in vitro. 35 To test the effects of SB431542 and XAV939 on human cardiac reprogramming induced by 7F in the most relevant type of fibroblasts, we generated a reversibly immortalized cell line of adult human cardiac fibroblasts. We did this by introducing a puromycin-resistant floxed T-antigen into primary adult cardiac fibroblasts and selecting for puromycin resistance. Viral introduction of Cre recombinase into the cell line resulted in efficient removal of the T antigen and reversal of the proliferative phenotype (Figure VA and VB in the online-only Data Supplement). Using the cardiac TNT-GCaMP reporter to detect cells reprogrammed to the point of having calcium transients (Figure 8A) , we found that 7F plus SB431542 and XAV939 (7Fc) doubled the percentage of iCMs reprogrammed by 7F ( Figure 8B ). iCMs reprogrammed with 7Fc also exhibited sarcomere formation as early as 3 weeks ( Figure 8C ). Furthermore, calcium sparks occurred after just 10 days of reprogramming with 7Fc (Movie VII in the online-only Data Supplement), and within 3 weeks of reprogramming, these calcium transients became more homogeneous throughout the cell. Within 4 weeks, >50% of 7Fc reprogrammed cells exhibited spontaneous calcium transients compared with <5% with 7F ( Figure 8D and Movie VIII in the online-only Data Supplement).
To assess the quality of reprogrammed cells, we performed RNA-seq on TNT-GFP-positive iCMs after 4 weeks of 7F-induced reprogramming with or without chemicals. The gene-expression profile changes in 7Fc iCMs were improved compared with 7F iCMs, as indicated by expression levels of the major cardiac and fibroblast genes in TNT-GFP-positive iCMs. We found that the chemicals enhanced the 7F effect on expression of cardiac genes and suppressed the expression of fibroblast genes ( Figure VC in the online-only Data Supplement). Furthermore, we performed GO analysis of the genes that were differentially regulated between the 7F and 7Fc iCMs by at least 2-fold and found that these genes were mostly involved in downregulation of extracellular matrix formation and collagens, as well as upregulation in calcium and ion transport-related genes, similar to that observed in mouse reprogramming ( Figure VD in the online-only Data Supplement).
We tested how removal of 1 or more of the TFs in 7Fc would affect gene expression in human cardiac fibroblasts expressing the remaining factors. By removing 1, 2, or 3 factors at a time ( Figure VI Supplement) and using quantitative real-time polymerase chain reaction Taqman assays ( Figure 8E ), and immunofluorescence revealed highly organized sarcomere organization in 4Fc iCMs, almost as organized as 7Fc iCMs as early as 3 weeks ( Figure 8F ). Furthermore, 4Fc iCMs showed calcium transients similar to 7Fc-induced iCMs (Movie IX in the online-only Data Supplement).
DISCUSSION
We performed an unbiased, high-throughput screen of small molecules in primary cardiac fibroblasts to identify barriers to cardiac cell-fate conversion that could be overcome to enhance efficiency and quality of GMTmediated cardiac reprogramming in vivo. We discovered that combinatorial inhibition of TGF-β and WNT signaling with SB431542 and XAV939 potently enhances the efficiency, quality, and speed of reprogrammed iCMs generated upon delivery of the minimal TF cocktail, GMT, into postnatal cardiac fibroblasts. Most important, these small molecules significantly improved in vivo reprogramming and cardiac function in mice compared with GMT alone and reduced the number of TFs needed for human reprogramming. Recent reports explored various combinations of TFs, 7-10 growth factors, 36 kinases, 12 small molecules, 13, 14 and microRNAs 11 to improve GMT-induced reprogramming in vitro. However, each of these reports used MEFs for screening, and although improved reprogramming efficiency was found in MEFs, the effect on postnatal mouse or human cardiac fibroblasts was limited, and no in vivo enhancement has been reported. In our study, we used primary cardiac fibroblasts for screening purposes and thereby report the first small-molecule cocktail that enhances direct cardiac reprogramming with the minimal TF cocktail in postnatal human and mouse cardiac fibroblasts in vitro and in vivo in a mouse cardiac injury model. Furthermore, in the presence of TGF-β and WNT inhibitors, we were able to reduce the number of TFs needed for human cardiac reprogramming to only 4 factors. Increasing the efficiency, speed, and quality of direct cardiac reprogramming and reducing the number of TFs needed for human reprogramming may facilitate further clinical application for the direct cardiac reprogramming strategy in heart failure treatment.
The multiple chemical compounds annotated to affect TGF-β or WNT signaling pathways at distinct steps provided confidence that these pathways were involved in cardiac reprogramming. The most robust TGF-β inhibitor, SB431542, selectively inhibits ALK5 (the TGF-β type I receptor), ALK4, and ALK7. 22 The observation that TGF-β ligand reverses the effects of SB431542 and ALK5 siRNA mimics the effects and the transcriptome data demonstrating suppression of the TGF-β pathway by the inhibitor together support TFG-β signaling as the relevant target of SB431542. Previous reports showed that SB431542 enhances in vitro direct cardiac reprogramming of MEFs induced by a TF cocktail containing GMT, Hand2, and Nkx2-5 but has little effect on postnatal cardiac fibroblasts. 13, 14 The additional TFs may limit the function of SB431542 when introduced into cardiac fibroblasts compared with MEFs.
WNT signaling occurs through 3 major pathways: canonical, noncanonical planar-cell polarity, and noncanonical WNT/calcium. In the canonical pathway, WNT binds frizzled to disrupt the function of a complex that targets β-catenin for ubiquitination and degradation in the proteasome. It is interesting to note that biphasic modulation of canonical WNT signaling during stem cell differentiation into cardiomyocytes promotes mesoderm differentiation and produces a high yield of pure cardiomyocytes. 37, 38 The most potent WNT inhibitor, XAV939, is a tankyrase inhibitor that inhibits Wnt signaling via axin stabilization, resulting in degradation of β-catenin. The reversal of the effects of XAV939 by WNT activation with a glycogen synthase kinase 3β inhibitor (CHIR99021) supports the notion that inhibition of Wnt signaling promotes cardiac reprogramming. In another context, CHIR99021, which enhances Wnt signaling, has been shown to cooperate with additional small molecules to replace the induced pluripotent stem cell reprogramming factors (OCT4, SOX2, cMYC, and KLF4) as a means to induce an epigenetically unstable state. Subsequent treatment with cardiogenic factors (BMP/activin/vascular endothelial growth factor) enabled cardiogenesis and produced cardiomyocyte-like cells. 18, 39 However, the cellular path involving reprogramming toward pluripotency is fundamentally different compared with the direct reprogramming to a cardiomyocyte in the presence of GMT, perhaps explaining the enhancement of cardiac reprogramming with Wnt inhibition rather than Wnt activation.
Ongoing genome-wide studies will reveal how Smad and TCF proteins, TFs that mediate TGF-β and WNT signaling, respectively, function cooperatively with GMT to regulate the conversion of fibroblasts to the cardiac fate. However, the primary analysis of GO terms enrichment analysis of the RNA-seq data from reprogrammed iCMs in the presence of SB431542, XAV939, or SB431542+XAV939 highlighted the major downstream effects of the compounds associated with increased efficiency of reprogramming. SB431542-reprogrammed iCMs showed mainly downregulation in fibrotic signal and extracellular matrix formation, consistent with previous reports in other reprogramming settings. 13, 14 In contrast, XAV939-reprogrammed iCMs showed downregulation in genes involved in chromatin modulation, DNA packaging, and nucleosome organization, similar to previous reports in other cell types. 32 It is interesting to note that our RNA-seq data revealed that in vitro and in vivo GMTc iCMs have a gene expression profile more consistent with adult ventricular cardiomyocytes than neonatal cardiomyocytes. It is surprising that the RNA expression levels of certain cardiac genes in GMTc iCMs in vitro and in vivo were actually higher than in isolated control endogenous cardiomyocytes (eg, TNNT, ACTC1, ACTN2, MYH7, and RYR2; Figure 4D and 7F). This unexpected observation could reflect that iCMs are still undergoing reprogramming and therefore are actively transcribing higher levels of these lineagespecific genes to support their cell-fate transformation. Alternatively, these genes may represent targets that are particularly sensitive to the sustained activity of exogenous GMT and would suggest that transient expression would be preferable as translation of this technology progresses.
Direct cardiac reprogramming is an approach to cardiac regeneration that has potential to become a novel therapy for heart failure. However, many challenges remain that will require ongoing innovation, including improved delivery systems, regulation of timing for expression of reprogramming factors, and testing in more chronic conditions. In the current study, we present the translational potential of this technology with the help of small molecules in vivo and in human cells. Although our experiments showed the first proof of principle of small-molecule enhancement of in vivo reprogramming, further studies are needed to optimize the dosages and timing for the small molecules to achieve the greatest outcome. At present, several TGF-β and WNT inhibitors are in clinical trials, 40, 41 which will aid the translational use of these inhibitors for cardiac reprogramming in the future. Together, these findings may facilitate combined gene and small-molecule therapy for heart regeneration.
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